Cross RW., Longini IM., Becker S., Bok K., Boucher D., Carroll MW., Díaz JV., Dowling WE., Draghia-Akli R., Duworko JT., Dye JM., Egan MA., Fast P., Finan A., Finch C., Fleming TR., Fusco J., Geisbert TW., Griffiths A., Günther S., Hensley LE., Honko A., Hunegnaw R., Jakubik J., Ledgerwood J., Luhn K., Matassov D., Meshulam J., Nelson EV., Parks CL., Rustomjee R., Safronetz D., Schwartz LM., Smith D., Smock P., Sow Y., Spiropoulou CF., Sullivan NJ., Warfield KL., Wolfe D., Woolsey C., Zahn R., Henao-Restrepo AM., Muñoz-Fontela C., Marzi A.

The emergence of Marburg virus (MARV) in Guinea and Ghana triggered the assembly of the MARV vaccine "MARVAC" consortium representing leaders in the field of vaccine research and development aiming to facilitate a rapid response to this infectious disease threat. Here, we discuss current progress, challenges, and future directions for MARV vaccines.

An introduction to the Marburg virus vaccine consortium, MARVAC.

DOI

Type

Journal

Publication Date

Volume

Addresses

Keywords